Conflict of interest: K.A.K.: speaker fees: Zoll Medical and Daiichi Sankyo; travel support: Amgen; consulting fees: Novartis and Amarin. G.M.-G.: consulting fees: Novartis, JAMP Pharma, Boston Scientific, KYE, Pendopharm, and HLS; speaker fees: Novartis, Bayer, Boston Scientific, JAMP Pharma, Pendopharm, HLS, KYE, and CIS. J.B.G.: grants/contracts: Merck, Roche, Boehringer Ingelheim, Lilly, Sanofi/Lexicon; consulting fees: Astra Zeneca, Bayer, Boehringer Ingelheim, Lilly, Novo Nordisk, Pfizer, Anji, Valo, and Vertex; lecture fees: Boehringer Ingelheim. L.A.L.: grants/contracts: Lexicon; consulting fees: Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, Pfizer, and Sanofi; lecture fees: Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Servier. R.D.L.: grants/contracts: BMS, GSK, Medtronic, Pfizer, and Sanofi; consulting fees: Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Portola, Glaxo Smith Kline, Medtronic, Merck, Pfizer, and Sanofi; travel support: BMS and GSK. S.D.P.: grants/contracts: Astra Zeneca and Boehringer Ingelheim; consulting fees: Abbott, Amarin Corporation, Applied Therapeutics, Eli Lilly & Co, Hengrui Pharmaceuticals, Menarinii International, Novo Nordisk, Sun Pharmaceuticals, and Evaharma; lecture fees: AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co, Merck Sharpe & Dohme, Novartis Pharmaceuticals, Novo Nordisk, Sanofi, and Laboratori Guidotti. J.J.V.M.: grants: British Heart Foundation Centre of Research Excellence Grant RE/18/6/34217; fees for consulting and other activities: Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardurion, Cytokinetics, Dal-Cor, GlaxoSmithKline, Ionis, KBP Biosciences, Novartis, Pfizer, and Theracos; personal lecture fees: Corpus, Abbott, Hikma, Sun Pharmaceuticals, Medscape/Heart.Org, Radcliffe Cardiology, Servier Director, and Global Clinical Trial Partners (GCTP). A.F.H.: research grants: Merck, Astra Zeneca, Novartis, and Verily; honoraria: Merck, Bayer, Amgen, Astra Zeneca, and Novartis. C.B.G.: consulting fees: Abbvie, Abiomed, Alnylam, Anthos, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardionomic, Celecor Therapeutics, Hengrui USA, Janssen, Medscape, Medtronic, Merck, NephroSynergy, Novo Nordisk, NIH, Novartis, Pfizer, Philips, and REATA; grants/contracts: Boehringer Ingelheim, Bristol Myers Squibb, FDA, Janssen, Lilly, Novartis, Pfizer, and Philips; equity: Tenac.io. The remaining authors declare no conflict of interest.
PubMed
